Verici Dx (LON:VRCI) is no longer just a diagnostics innovator—it’s a commercial-stage disruptor with momentum. In this interview, CEO Sara Barrington outlines how their flagship RNA-based test, Tutivia, is outperforming legacy transplant diagnostics, not only in validation trials but now in real-world use. With reimbursement locked in, early commercial traction, and a clear runway to capture a $900M addressable market, Verici Dx is positioned to redefine transplant care. Add in licensing success with Thermo Fisher (Clarava) and pipeline expansion toward fibrosis and urine-based diagnostics, and this is one growth story investors should be watching closely.Key Moments:

• 00:11 – Interview begins with Sara Barrington, CEO of Verici Dx
• 00:38 – Focus on transplant diagnostics and AI-powered RNA testing
• 01:53 – Why Verici started with kidney transplant and how Clarava (pre-transplant test) fits in
• 02:48 – Tutivia’s role in post-transplant rejection detection
• 04:05 – Overview of test pipeline and unmet clinical needs
• 04:26 – What de-risked and ready for scale-up actually means
• 05:26 – Reimbursement wins including Medicare and Palmetto coverage
• 07:03 – Why validation was intentionally high-risk to gain clinical trust
• 08:20 – Unmatched comprehensiveness vs competitors
• 09:55 – Financial positioning and alignment with investor expectations
• 11:03 – Capital focused on sales, marketing, and KOL engagement
• 12:04 – $900M US market opportunity and Verici’s strategic entry points
• 14:08 – Tutivia’s advantage in early-stage rejection vs. cell-free DNA rivals
• 15:20 – Commercial ramp: scaling sales team from 4 to 15
• 17:09 – Expected news flow: centre expansion, payer contracts, and commercial traction